Mounjaro Vs Trulicity

If you are trying to decide between two injectable medications for weight loss or type 2 diabetes management, you are not alone. Thousands of people across the UK are currently weighing up Mounjaro vs Trulicity, trying to work out which injection offers better results, fewer side effects, and greater value for money. Both treatments work by targeting hormones involved in blood sugar regulation and appetite control, but they differ in important ways that could make one a significantly better fit for your personal health goals than the other.

Quick Summary

Mounjaro (tirzepatide) and Trulicity (dulaglutide) are both once-weekly injectable medications used to manage type 2 diabetes and support weight loss, but they work through different mechanisms and produce very different clinical outcomes. Mounjaro activates both GIP and GLP-1 receptors, making it a dual-action treatment, whereas Trulicity acts on GLP-1 receptors alone.

• Mounjaro produces significantly greater weight loss than Trulicity across clinical trials
• Both medications are injected once weekly using pre-filled pens
• Mounjaro is licensed in the UK for both type 2 diabetes and weight management
• Trulicity is primarily licensed for type 2 diabetes, with more modest weight loss benefits
• Your prescriber will help determine which option is clinically appropriate for your needs

Table of Contents

• What Are Mounjaro and Trulicity?
• How Do They Work Differently?
• Mounjaro vs Trulicity: Weight Loss Results Compared
• Side Effects and Tolerability
• Dosing, Administration, and UK Availability
• Who Should Choose Mounjaro and Who Should Choose Trulicity?
• Full Comparison Table
• Key Takeaways
• When to Seek Professional Advice
• Scientific References
• FAQs

What Are Mounjaro and Trulicity?

Mounjaro is the brand name for tirzepatide, a relatively new injectable medication developed by Eli Lilly. It was approved by the MHRA in the UK for type 2 diabetes management and has since gained a licence for chronic weight management under the brand name Mounjaro. It is one of the most talked-about treatments in 2026 because of its remarkable clinical weight loss data. Tirzepatide works as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, meaning it activates two separate hormonal pathways simultaneously.

Trulicity is the brand name for dulaglutide, also manufactured by Eli Lilly. It has been available in the UK for longer and is primarily prescribed for adults with type 2 diabetes to improve blood sugar control and reduce the risk of cardiovascular events. Trulicity works exclusively as a GLP-1 receptor agonist. When comparing Mounjaro vs Trulicity, this fundamental difference in mechanism is one of the most important factors to understand because it underpins the difference in their clinical effectiveness, particularly for weight loss.

Both medications are administered as once-weekly subcutaneous injections. Both come in pre-filled injection pens, making them relatively straightforward to use at home without the need for clinic visits for each dose. However, their eligibility criteria, dose ranges, and outcomes differ considerably, which is why many patients and prescribers are now actively comparing the two.

• Mounjaro (tirzepatide) — dual GIP and GLP-1 receptor agonist
• Trulicity (dulaglutide) — single GLP-1 receptor agonist
• Both manufactured by Eli Lilly
• Both given as once-weekly injections
• Licensed indications differ — Mounjaro now covers weight management

How Do They Work Differently?

To properly understand the difference between these two medications, it helps to understand how each one interacts with the body's hormonal systems. GLP-1 (glucagon-like peptide-1) is a gut hormone that is naturally released after eating. It stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite by acting on receptors in the brain. Both Mounjaro and Trulicity activate these GLP-1 receptors, which is why they share some similar effects such as improved blood sugar control and reduced appetite.

Where Mounjaro differs is its additional action on GIP receptors. GIP (glucose-dependent insulinotropic polypeptide) is another incretin hormone released from the small intestine in response to food. It enhances insulin secretion and plays a role in fat metabolism. By activating both GIP and GLP-1 pathways, tirzepatide produces a more powerful and synergistic effect on appetite suppression, caloric intake reduction, and metabolic rate than a GLP-1 agonist alone. This is why clinical trial data consistently shows Mounjaro producing greater weight loss than single-action GLP-1 medications including Trulicity.

Trulicity's mechanism, while effective, is more limited because it targets only one of these hormonal pathways. For patients with type 2 diabetes who need better glycaemic control and modest weight reduction, Trulicity remains a clinically sound option. But for those whose primary goal is substantial weight loss, the dual-action approach of Mounjaro offers a meaningful biological advantage. If you are also looking at orlistat-based weight loss aids as a comparison, it is worth noting that injectable GLP-1 medications generally produce more consistent outcomes than oral fat-binding treatments.

• GLP-1 activation reduces appetite and slows digestion in both medications
• Mounjaro's additional GIP action boosts fat metabolism and insulin response
• Dual-receptor activation leads to enhanced appetite suppression
• Trulicity's single-action mechanism is effective but less potent for weight loss

Mounjaro vs Trulicity: Weight Loss Results Compared

This is where the data becomes genuinely compelling. In the SURMOUNT clinical trial programme, tirzepatide (Mounjaro) produced average weight loss of up to 22.5% of body weight over 72 weeks at the highest dose of 15mg. Even at the lowest maintenance dose of 5mg, participants lost an average of around 15% of their body weight. These are figures that were previously only seen in bariatric surgery outcomes, not in pharmacological treatments.

By contrast, Trulicity's weight loss data is considerably more modest. In clinical trials, dulaglutide produced average weight loss of approximately 3 to 5 kilograms over a 52-week period. While this is clinically meaningful and often welcomed by patients managing type 2 diabetes, it falls well short of what tirzepatide delivers. For someone weighing 100kg, this translates to roughly 3 to 5% body weight reduction with Trulicity, versus potentially 15 to 22% with Mounjaro.

When directly comparing Mounjaro vs Trulicity in head-to-head trials, tirzepatide consistently outperformed dulaglutide on both HbA1c reduction and weight loss across all doses tested. The SURPASS-2 trial, which directly compared the two medications, found that tirzepatide at all three doses (5mg, 10mg, and 15mg) produced statistically significantly greater reductions in body weight and blood glucose than dulaglutide at 1.5mg. If you want to explore additional non-prescription support alongside your treatment, XLS Medical Weight Loss Plus tablets or XLS Medical Direct Fat Binder sachets can complement a broader weight management plan under professional guidance.

• Mounjaro: average weight loss of 15–22.5% over 72 weeks in SURMOUNT trials
• Trulicity: average weight loss of 3–5% over 52 weeks in clinical trials
• SURPASS-2 showed tirzepatide superior at all doses versus dulaglutide 1.5mg
• HbA1c reductions were also greater with Mounjaro across all comparison studies
• Weight loss gap between the two widens further at higher Mounjaro doses

Side Effects and Tolerability of Each Medication

One of the most common questions people ask when choosing between injectable weight loss treatments is about side effects. Both Mounjaro and Trulicity share a similar gastrointestinal side effect profile because they both act on GLP-1 receptors, which slow gastric emptying. The most commonly reported side effects for both medications include nausea, vomiting, diarrhoea, constipation, and reduced appetite. These tend to be most pronounced in the early weeks of treatment and usually improve as the body adjusts to each dose level.

For Mounjaro, because it also activates GIP receptors, there is an argument that its tolerability is actually comparable to or slightly better than some other GLP-1 medications, despite producing greater clinical effects. In the SURPASS trials, the rate of discontinuation due to gastrointestinal side effects was broadly similar to that seen with dulaglutide. Nausea was reported by approximately 17 to 22% of Mounjaro users, compared to 13 to 14% for Trulicity users — a modest difference.

Injection site reactions such as redness, itching, or mild swelling are possible with both medications. Both drugs also carry a theoretical risk of pancreatitis, medullary thyroid carcinoma (particularly in those with a personal or family history), and hypoglycaemia when used alongside other diabetes medications such as sulphonylureas or insulin. Neither medication should be used during pregnancy. It is important to have a thyroid assessment if there are any concerns — a thyroid test can help establish a baseline before starting either treatment.

• Nausea is the most common side effect with both medications
• Symptoms are usually temporary and improve after dose stabilisation
• Both carry warnings for pancreatitis and thyroid-related risks
• Hypoglycaemia risk is higher when combined with sulphonylureas or insulin
• Injection site reactions are mild and generally self-resolving

Dosing, Administration, and UK Availability in 2026

In 2026, both medications are available in the UK through prescription routes. Mounjaro is available as a pre-filled KwikPen in doses of 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg. The standard starting dose for weight management is 2.5mg weekly for the first four weeks, followed by a dose escalation every four weeks until the target maintenance dose is reached. The maximum approved dose is 15mg weekly. This gradual titration schedule is specifically designed to minimise gastrointestinal side effects during the adjustment period.

Trulicity is available in doses of 0.75mg and 1.5mg for type 2 diabetes, with a 3mg and 4.5mg dose also available for patients who need additional glycaemic control. The starting dose is typically 0.75mg once weekly, titrated up to 1.5mg after four weeks if tolerated. Trulicity also comes as a pre-filled single-use pen and is injected subcutaneously in the abdomen, thigh, or upper arm — the same sites as Mounjaro. The injection technique is broadly similar for both, making a switch between medications relatively straightforward from a practical standpoint.

On the NHS, Mounjaro is available through specialist weight management services and some GP practices for eligible patients with a BMI of 35 or above plus at least one weight-related comorbidity. Trulicity is more widely available on the NHS for type 2 diabetes management. Privately, Mounjaro can be accessed through regulated online pharmacies and prescribing services, and Trulicity is typically accessed via private GP or specialist diabetes clinics. Many patients looking to support their treatment with lifestyle interventions also explore Alli weight loss capsules as a non-prescription complement — though always under professional guidance.

• Mounjaro doses: 2.5mg to 15mg weekly, titrated over several months
• Trulicity doses: 0.75mg to 4.5mg weekly for diabetes management
• Both injected subcutaneously once weekly using pre-filled pens
• Mounjaro available privately through regulated UK online pharmacies
• NHS access for Mounjaro requires meeting specific clinical eligibility criteria

Who Should Choose Mounjaro and Who Should Choose Trulicity?

Choosing between these two medications depends heavily on your individual health goals, medical history, and what you are hoping to achieve from treatment. If your primary goal is significant weight loss — for instance, you have a BMI above 30 and want to lose a meaningful percentage of your body weight — Mounjaro is likely the more appropriate choice based on available clinical evidence. Its superior weight loss outcomes and its specific UK licence for chronic weight management make it the go-to injectable option for many patients in this category.

Trulicity may be more suitable for patients whose primary concern is type 2 diabetes management rather than weight loss, particularly those who have established cardiovascular disease. The REWIND trial demonstrated that dulaglutide reduced the risk of major adverse cardiovascular events in people with type 2 diabetes and established or risk factors for cardiovascular disease. While Mounjaro is also being studied for cardiovascular outcomes, Trulicity's cardiovascular data is more established given its longer time on the market.

Some patients may also prefer Trulicity if they have previously tried more potent GLP-1 medications and experienced difficult side effects at higher doses, as Trulicity's lower potency may mean a gentler tolerability profile for those individuals. Conversely, patients who have previously tried Trulicity or another GLP-1 medication without achieving satisfactory weight loss are often good candidates for switching to Mounjaro, as its dual-action mechanism may provide the additional effect they were missing. Patients managing related metabolic conditions may also benefit from checking the Formoline L112 tablets as a dietary fibre supplement to support blood sugar management alongside medical treatment.

• Choose Mounjaro if significant weight loss is your primary goal
• Consider Trulicity if cardiovascular risk reduction alongside diabetes management is the priority
• Mounjaro may be preferred if previous GLP-1 therapy was insufficient
• Trulicity may suit patients who need a gentler medication with established long-term data
• A prescriber should always guide the final decision based on your full clinical profile

Full Mounjaro vs Trulicity Comparison Table

Feature	Mounjaro (Tirzepatide)	Trulicity (Dulaglutide)
Drug class	Dual GIP and GLP-1 receptor agonist	GLP-1 receptor agonist
UK licence	Type 2 diabetes and chronic weight management	Type 2 diabetes
Injection frequency	Once weekly	Once weekly
Starting dose	2.5mg weekly	0.75mg weekly
Maximum dose	15mg weekly	4.5mg weekly
Average weight loss	15–22.5% body weight	3–5% body weight
HbA1c reduction	Up to 2.3% reduction	Up to 1.5% reduction
Cardiovascular outcome data	Ongoing trials (2026)	Established — REWIND trial
Common side effects	Nausea, vomiting, diarrhoea, constipation	Nausea, vomiting, diarrhoea, constipation
NHS availability	Specialist services, BMI criteria apply	Widely available via GP
Private prescription	Available — from £145 at Cured Pharmacy	Available via private clinics
Pen device	KwikPen (pre-filled)	Single-use autoinjector pen
Storage	Refrigerated (2–8°C)	Refrigerated (2–8°C)

Key Takeaways

• Mounjaro's dual GIP and GLP-1 mechanism produces superior weight loss results compared to Trulicity's single GLP-1 action
• In the SURPASS-2 head-to-head trial, tirzepatide outperformed dulaglutide on both weight and blood sugar outcomes at every dose tested
• Trulicity has more established cardiovascular outcome data, making it a strong choice for patients with known heart disease alongside diabetes
• Both medications are well-tolerated with similar gastrointestinal side effect profiles, particularly during dose escalation periods
• A prescriber consultation is essential before starting either medication, as individual suitability, contraindications, and goals must all be considered

When to Seek Professional Advice

You should always speak to a qualified prescriber before starting or switching either of these medications. This is particularly important if you have a personal or family history of medullary thyroid carcinoma, pancreatitis, severe gastrointestinal disease, or if you are taking other diabetes medications that carry a hypoglycaemia risk. If you experience severe or persistent abdominal pain, vomiting that prevents you from keeping fluids down, or signs of an allergic reaction such as swelling, hives, or difficulty breathing, you should seek urgent medical attention and stop the medication.

If you are currently using Trulicity and feel it is not delivering the weight loss or diabetes control you need, speak to your prescriber about whether tirzepatide may be a more appropriate option for you. Online prescribing services such as those available at Cured Pharmacy allow you to complete a medical consultation from home, with a review conducted by a UK-registered prescribing pharmacist. This makes it straightforward to explore your options safely, without the need for a GP appointment in many cases.

Scientific References

1. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. The Lancet, 2022.
3. National Institute for Health and Care Excellence (NICE). Dulaglutide for treating type 2 diabetes. Technology Appraisal Guidance TA664. NICE, UK.

Frequently Asked Questions

How long does it take to see results with Mounjaro compared to Trulicity?

Results with Mounjaro compared to Trulicity typically appear within the first four to eight weeks. Mounjaro users often notice appetite reduction within days, while meaningful weight loss usually becomes visible after six to twelve weeks. Trulicity users may see blood sugar improvements sooner, though weight loss tends to be more modest overall.

Is Mounjaro safer than Trulicity for long-term use?

Mounjaro is considered safe for long-term use, with clinical trial data supporting its efficacy and safety profile over 72 weeks. Trulicity has a longer post-market history in the UK. Both carry similar gastrointestinal side effect risks, though Mounjaro's dual-action mechanism has been associated with greater metabolic benefits over time.

Can you switch from Trulicity to Mounjaro?

Yes, you can switch from Trulicity to Mounjaro, but this must be done under the supervision of a prescriber. When switching from Trulicity to Mounjaro, your prescriber will typically start you on the lowest Mounjaro dose and monitor your response before any dose escalation is considered.

What is the starting dose of Mounjaro for weight loss in the UK?

The starting dose of Mounjaro for weight loss in the UK is 2.5mg once weekly, injected subcutaneously. After four weeks, the dose is typically increased to 5mg weekly. Further escalation to 7.5mg, 10mg, 12.5mg, and up to 15mg follows based on tolerance and clinical response.